Leading Pharma Third Party Manufacturer

NPPA Caps Trade Margins on 137 Anti-Cancer Drugs in India | 2026 Update

Understand the latest NPPA 2026 update on trade margin rationalization for 137 non-scheduled anti-cancer drugs in India. Learn about the 30% trade margin cap, revised MRP calculation, effective date of 9 November 2026, and key compliance requirements for pharmaceutical companies. Explore practical insights from Ogiso Lifesciences Pvt. Ltd., your partner for pharmaceutical third-party manufacturing in India.

PHARMACEUTICAL BUSINESS

jp sharma

10/21/20269 min read

NPPA Trade Margin Cap on 137 Anti-Cancer Drugs: A Simple Guide for Pharma Companies

Introduction: A Step Towards More Affordable Cancer Treatment

Cancer treatment can be financially challenging for patients and their families. The cost of medicines is one of the important factors that can add to this burden, particularly when treatment continues over a long period.

To address concerns about high trade margins on certain cancer medicines, the National Pharmaceutical Pricing Authority (NPPA) has introduced a new regulatory measure covering 137 non-scheduled anti-cancer drugs.

The order, S.O. 5690(E), dated 17 October 2026, establishes a maximum trade margin of 30% for specified formulations containing the listed drugs. The revised prices are scheduled to take effect from 9 November 2026.

For pharmaceutical manufacturers, marketing companies, stockists, distributors and hospitals, understanding this order is important for planning prices, updating records and maintaining regulatory compliance.

At Ogiso Lifesciences Pvt. Ltd., we believe that understanding pharmaceutical regulations is an important part of building a responsible and sustainable pharmaceutical business.

Let us understand what this new NPPA order means in simple language.

1. What Is the NPPA?

The National Pharmaceutical Pricing Authority (NPPA) is a government authority responsible for implementing and enforcing drug pricing regulations under the Drugs (Prices Control) Order, 2013 (DPCO).

Its work includes regulating prices where applicable, monitoring medicine prices and taking action when the pricing rules are violated.

The objective is to help ensure that essential medicines remain available at reasonable prices while supporting a properly regulated pharmaceutical market.

2. What Is the New NPPA Order of 17 October 2026?

Under S.O. 5690(E), the government has invoked Paragraph 19 of the DPCO, 2013, to rationalise trade margins on selected non-scheduled anti-cancer formulations.

The order covers 137 specified anti-cancer drugs, identified in the notification's accompanying list.

The main provisions are:

A maximum trade margin of 30% is prescribed for covered formulations.
The revised maximum retail price (MRP) is calculated using the prescribed formula and the applicable March 2026 price-to-stockist or price-to-distributor reference.
The revised prices take effect from 9 November 2026.
Manufacturers must submit the required revised MRP information within seven days of publication of the order.
Companies must issue and distribute revised price lists as required by the order.

The purpose is to reduce excessive trade mark-ups and improve affordability for patients.

Important: This is a specific pricing intervention for the formulations covered by the notification. It should not be interpreted as a 30% margin cap on every medicine sold in India.

3. Which Anti-Cancer Medicines Are Covered?

The order identifies 137 drugs for inclusion in the trade margin rationalisation exercise.

Examples from the list include:

Abemaciclib
Abiraterone acetate
Anastrozole
Erlotinib
Everolimus
Imatinib
Lenalidomide
Nivolumab
Olaparib
Palbociclib
Pembrolizumab
Pemetrexed
Sunitinib
Trastuzumab
Venetoclax

These medicines are used in different cancer treatment settings. The list also contains many other medicines and combinations.

The order has a broad formulation-level application. If a non-scheduled formulation contains a listed drug, the prescribed pricing mechanism applies regardless of its strength, dosage form or route of administration. It also applies when the listed drug is combined with other ingredients or when the formulation is used for another therapeutic indication.

Therefore, pharmaceutical companies should review their complete product portfolios against the official list instead of checking only products marketed specifically for cancer treatment.

4. How Is the New MRP Calculated?

One of the most important aspects of the order is the method used to calculate the revised maximum retail price.

The formula prescribed in the notification is:

MRP = PTS/PTD × {1 + [TM ÷ (100 − TM)]} + applicable GST

Where:

MRP: Maximum retail price.
PTS/PTD: Price to stockist or price to distributor, based on the prescribed March 2026 reference.
TM: Trade margin, which cannot exceed 30%.
GST: Applicable goods and services tax.

The formula is important because the 30% limit is not simply calculated by adding 30% to the stockist or distributor price. The formula works out the permitted MRP using the specified trade margin and the applicable GST.

Example from the NPPA order

The notification provides the following illustration:

ParticularsAmountExisting MRP, excluding applicable GST₹300Reference PTS/PTD₹70Maximum permitted MRP, excluding GST₹100Applicable GSTAdded separately

Using the prescribed formula:

₹70 × {1 + [30 ÷ (100 − 30)]} = ₹100

Therefore, the maximum permitted MRP in this example is ₹100 plus applicable GST.

If a product's existing MRP is higher than the newly calculated permitted MRP, the manufacturer must reduce it accordingly. If the existing MRP is already lower than the calculated limit, the order allows the existing lower MRP to be retained.

Companies should calculate prices using their actual product-specific data and the complete requirements of the notification.

5. When Do the New Prices Become Effective?

The revised prices under this order are scheduled to become effective on 9 November 2026.

Manufacturers must also meet the notification's reporting and price-list distribution requirements.

Key actions include:

Identify every covered formulation.
Calculate the revised MRP using the prescribed formula.
Submit the revised MRP information to NPPA and the concerned State Drug Controller within seven days of publication of the order.
Issue the applicable revised price list in Form V through the Integrated Pharmaceutical Database Management System (IPDMS).
Provide the required price-list copies to distributors, retailers and other relevant parties.
Ensure that the applicable revised prices are displayed as required by the order.

The order also requires appropriate communication of price reductions, including newspaper advertisements and information on the company's website within the specified period.

Manufacturers should retain records demonstrating compliance and the distribution of revised prices.

6. What Should Pharmaceutical Manufacturers and Marketing Companies Do?

The new order requires more than a simple change to the printed MRP. Companies should review their pricing, documentation and distribution processes together.

Review the product portfolio

Prepare a list of all products containing any of the 137 specified drugs. Include different strengths, dosage forms, combinations and relevant indications.

Recalculate the MRP

Use the applicable PTS/PTD reference and the formula provided in the order. Do not assume that every product can be adjusted by applying a flat percentage reduction.

Coordinate with distributors

Share revised price lists and communicate the effective date clearly. Review available stock and billing systems so that the applicable prices are followed.

Update internal records

Maintain product-wise price calculations, approved price lists, submissions, supporting invoices and communication records. Ensure that the regulatory, finance, sales and distribution teams work with consistent information.

Maintain product availability

The order requires manufacturers to maintain existing production levels. A manufacturer intending to reduce average monthly production must obtain prior NPPA permission. Discontinuation of production or import is subject to the prescribed advance notification requirements.

The company should review these obligations before making production or supply decisions.

7. What Does This Mean for the Indian Pharmaceutical Industry?

Trade margin rationalisation can influence several parts of the pharmaceutical supply chain.

For patients: The measure is intended to reduce excessive trade mark-ups on covered medicines and support more affordable treatment.

For manufacturers: Pricing calculations, documentation and communication become important compliance responsibilities.

For distributors and stockists: Updated price information and appropriate billing practices are essential.

For hospitals and medical institutions: The order specifically addresses direct supplies to hospitals and medical institutions, which are treated as stockists or distributors for the prescribed MRP calculation. They must monitor and comply with the applicable revised prices.

The order also provides for monitoring by State Drug Controllers and recovery of overcharged amounts under the applicable provisions in cases of violation.

The practical impact will depend on the products covered, their existing prices, supply arrangements and implementation of the order.

8. What Is the Role of Pharmaceutical Third-Party Manufacturing in India?

Pharmaceutical third-party manufacturing allows a company to get medicines manufactured by an external pharmaceutical manufacturer rather than establishing and operating its own manufacturing facility.

It can be useful for pharmaceutical marketing companies, new pharma businesses, established brands and companies looking to expand their product portfolios.

However, third-party manufacturing does not remove the need to understand regulatory responsibilities.

Where a covered product is manufactured by one company and marketed by another, both parties should clearly establish who will manage product-specific pricing calculations, regulatory submissions, price-list updates and market communication, according to their respective legal responsibilities.

Companies should also ensure that product approvals, manufacturing arrangements, quality documentation and applicable pricing requirements are reviewed before launching or continuing a product.

How Ogiso Lifesciences Pvt. Ltd. Supports Pharmaceutical Manufacturing

Ogiso Lifesciences Pvt. Ltd. is a pharmaceutical third-party manufacturing company based in Dholpur, Rajasthan.

The company offers manufacturing capabilities across several dosage forms, including:

Tablets and capsules
Syrups and suspensions
Ointments
Protein powders
Ayurvedic formulations

The company's facility includes manufacturing areas, clean rooms and quality-control laboratories, including microbiological, chemical and instrumental testing facilities. Ogiso Lifesciences holds WHO-GMP certification and a ZED certificate, as stated in its company information.

For businesses exploring pharmaceutical contract manufacturing in India, selecting a manufacturing partner involves evaluating the required dosage forms, product approvals, quality systems, production capabilities and commercial requirements.

Ogiso Lifesciences encourages prospective partners to discuss their specific product and documentation needs so that manufacturing requirements can be evaluated appropriately.

Learn more: https://ogisolifesciences.in/

9. Why Regulatory Awareness Matters for Third-Party Pharma Manufacturing

The pharmaceutical industry operates within a changing regulatory environment. Pricing requirements, product approvals, labelling rules and quality standards can all affect how a product is manufactured and marketed.

For companies working with a third-party pharma manufacturer, it is helpful to:

Review applicable regulations before finalising a product portfolio.
Define responsibilities between the marketing company and manufacturing partner.
Keep product and pricing documentation organised.
Communicate regulatory changes promptly.
Verify the current requirements with the relevant authority or regulatory professional.

These practices support better planning and can help reduce avoidable compliance issues.

The NPPA's October 2026 order is a reminder that pharmaceutical businesses must consider both product quality and the regulatory framework governing the sale of medicines.

Conclusion

The NPPA's S.O. 5690(E), dated 17 October 2026, introduces a maximum trade margin of 30% for specified non-scheduled anti-cancer formulations containing any of 137 listed drugs.

With revised prices scheduled to take effect from 9 November 2026, pharmaceutical companies should review the affected products, recalculate MRPs using the prescribed formula, update price lists and fulfil the required reporting and communication obligations.

For businesses seeking pharmaceutical third-party manufacturing in India, regulatory awareness is an important part of choosing and managing a manufacturing partnership.

At Ogiso Lifesciences Pvt. Ltd., we recognise the importance of quality-focused manufacturing, clear documentation and informed business decisions in the pharmaceutical sector.

Looking for a pharmaceutical third-party manufacturing partner in India? Visit https://ogisolifesciences.in/ to learn more about Ogiso Lifesciences and its manufacturing capabilities.

Frequently Asked Questions (FAQs)

1. What is the NPPA order dated 17 October 2026?

S.O. 5690(E) is an NPPA order that imposes a maximum 30% trade margin for specified non-scheduled anti-cancer formulations containing any of 137 listed drugs under Paragraph 19 of the DPCO, 2013.

2. Which 137 anti-cancer drugs are covered by the NPPA order?

The order provides a list of 137 drugs, including abemaciclib, anastrozole, erlotinib, imatinib, nivolumab, pembrolizumab, trastuzumab and venetoclax. Companies should refer to the complete official list to identify all affected products.

3. When does the new anti-cancer drug pricing order take effect?

The revised prices are scheduled to take effect from 9 November 2026.

4. How is the new MRP calculated under the NPPA order?

The MRP is calculated using the prescribed PTS/PTD-based formula, with a trade margin not exceeding 30%, plus applicable GST. The prescribed March 2026 PTS/PTD reference is used, subject to the order's specific provisions.

5. Does the 30% trade margin cap apply to all medicines in India?

No. This particular order covers specified non-scheduled formulations containing any of the 137 listed anti-cancer drugs. It is not a universal 30% trade margin cap for all medicines.

6. Does the order cover combination medicines containing a listed drug?

Yes. The order provides for application to covered formulations containing a listed drug, whether used alone or in combination, regardless of strength, dosage form or route of administration.

7. What must pharmaceutical manufacturers do under this order?

Manufacturers must identify affected formulations, calculate the permitted MRP, submit revised price information within the prescribed seven-day period, issue the required price lists, communicate changes and comply with the production and other obligations specified in the order.

8. Does the NPPA order apply to patented anti-cancer medicines?

The order states that patented medicines are also covered, unless an exemption has been approved under Paragraph 32 of the DPCO, 2013.

9. Can a pharmaceutical company continue selling a product at its existing lower MRP?

The order states that manufacturers whose existing MRP is lower than the MRP calculated under the prescribed formula should retain that lower existing MRP.

10. What is pharmaceutical third-party manufacturing?

Pharmaceutical third-party manufacturing is an arrangement in which a pharmaceutical company gets products manufactured by another qualified manufacturing company. The arrangement can help businesses build or expand a product portfolio without independently operating their own manufacturing facility.

11. How can I choose a pharmaceutical third-party manufacturing company in India?

Evaluate the manufacturer's applicable licences and certifications, dosage-form capabilities, quality systems, documentation, production capacity and suitability for your intended products. Also establish clear responsibilities for regulatory and pricing compliance.

12. Does Ogiso Lifesciences Pvt. Ltd. offer third-party pharmaceutical manufacturing?

Ogiso Lifesciences Pvt. Ltd. offers third-party pharmaceutical manufacturing across dosage forms including tablets, capsules, syrups, suspensions, ointments, protein powders and Ayurvedic formulations. Contact the company through its official website to discuss specific product requirements and manufacturing suitability.

Regulatory reference: Government of India, Ministry of Chemicals and Fertilizers, Department of Pharmaceuticals, National Pharmaceutical Pricing Authority, S.O. 5690(E), dated 17 October 2026. Consult the full notification for the complete list of covered drugs, formula, deadlines, exceptions and compliance conditions.

Disclaimer: This article is for general information and educational purposes only. It is not legal, regulatory or pricing advice. Pharmaceutical companies should review the complete official order and seek appropriate professional guidance before making pricing or compliance decisions.